Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Int J Mol Sci. 2023 May 3;24(9):8176. doi: 10.3390/ijms24098176.
Behcet's disease (BD) is a chronic and recurrent systemic vasculitis involving almost all organs and tissues. Intestinal BD is defined as BD with predominant gastrointestinal involvement, presenting severe complications such as massive gastrointestinal hemorrhage, perforation, and obstruction in some cases. To some extent, intestinal BD is classified as a member of inflammatory bowel disease (IBD), as it has a lot in common with classical IBD including Crohn's disease (CD) and ulcerative colitis (UC). Certainly, the underlying pathogenesis is not the same and dysregulation of immune function is believed to be one of the main pathogeneses in intestinal BD, although the etiology has not been clear up to now. Biological agents are an emerging category of pharmaceuticals for various diseases, including inflammatory diseases and cancers, in recent decades. Based on the deep understanding of the immune mechanism of intestinal BD, biological agents targeting potential pathogenic cells, cytokines and pathways are optimized options. Recently, the adoption of biological agents such as anti-tumor necrosis factor agents has allowed for the effective treatment of patients with refractory intestinal BD who show poor response to conventional medications and are faced with the risk of surgical treatment. In this review, we have tried to summarize the immune mechanism and present potential biological agents of intestinal BD.
贝赫切特病(BD)是一种慢性复发性全身血管炎,几乎涉及所有器官和组织。肠 BD 被定义为以胃肠道受累为主的 BD,在某些情况下会出现严重并发症,如大量胃肠道出血、穿孔和梗阻。在某种程度上,肠 BD 被归类为炎症性肠病(IBD)的一员,因为它与经典的 IBD 有很多共同之处,包括克罗恩病(CD)和溃疡性结肠炎(UC)。当然,潜在的发病机制并不相同,免疫功能失调被认为是肠 BD 的主要发病机制之一,尽管病因至今尚未明确。生物制剂是近几十年来治疗各种疾病(包括炎症性疾病和癌症)的一类新兴药物。基于对肠 BD 免疫机制的深入了解,针对潜在致病细胞、细胞因子和途径的生物制剂是优化选择。最近,采用抗肿瘤坏死因子等生物制剂可有效治疗对常规药物反应不佳且面临手术治疗风险的难治性肠 BD 患者。在这篇综述中,我们试图总结肠 BD 的免疫机制和目前潜在的生物制剂。